{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:17:37Z","timestamp":1791919057147,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:sec>\n            <jats:title>Background and Purpose\u2014<\/jats:title>\n            <jats:p>New therapies for cerebral vasospasm after subarachnoid hemorrhage are needed because of its high morbidity and mortality rates. We investigated the feasibility and safety of a single dose of intravenous dantrolene and its effect on transcranial Doppler in cerebral vasospasm after subarachnoid hemorrhage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\u2014<\/jats:title>\n            <jats:p>In a prospective, open-label, single-dose ascending safety trial, 5 patients received intravenous dantrolene 1.25 mg\/kg and the next 5 patients received 2.5 mg\/kg over the course of 60 minutes. All other infusions were kept steady and hemodynamic parameters were recorded. Transcranial Doppler was performed at 0, 45, 90, and 135 minutes relative to infusion start. Basic chemistries, serum osmolality, arterial blood gas, and liver enzymes were measured before and after.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results\u2014<\/jats:title>\n            <jats:p>\n              Laboratory values and hemodynamic parameters remained unchanged except for a decrease in the systolic blood pressure in the low-dose group (\u22128 mm Hg; 95% CI, \u221226 to 10 mm Hg;\n              <jats:italic>P<\/jats:italic>\n              =0.027). After correcting for this decrease in blood pressure, peak systolic transcranial Doppler velocities decreased significantly (\u221226 cm\/s; 95% CI, \u221247 to \u22125 cm\/s;\n              <jats:italic>P<\/jats:italic>\n              =0.02), with a borderline change in mean velocities in the low-dose group (\u221216 cm\/s; 95% CI, \u221236 to 4 cm\/s;\n              <jats:italic>P<\/jats:italic>\n              =0.07) and peak systolic transcranial Doppler velocity in the high-dose group (\u221226 cm\/s; 95% CI, \u221256 to 5 cm\/s;\n              <jats:italic>P<\/jats:italic>\n              =0.05).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>In this pilot study, a single dose of intravenous dantrolene in cerebral vasospasm after subarachnoid hemorrhage appears feasible while inhibiting vasoconstriction in the low-dose group, but it may lower blood pressure. Our study provides useful data for the design of larger future studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trial Registration\u2014<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">http:\/\/clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier: NCT00964548.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/strokeaha.110.603159","type":"journal-article","created":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T04:23:58Z","timestamp":1301631838000},"page":"1301-1306","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of a Single Dose of Dantrolene in Patients With Cerebral Vasospasm After Subarachnoid Hemorrhage"],"prefix":"10.1161","volume":"42","author":[{"given":"Susanne","family":"Muehlschlegel","sequence":"first","affiliation":[{"name":"From the Division of Neurocritical Care (S.M.), Departments of Neurology, Anesthesia\/Critical Care and Surgery, University of Massachusetts Medical School, Worcester, MA; Neurocritical Care Service, Departments of Neurology (G.R., J.S.) and Neurosurgery (J.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Rordorf","sequence":"additional","affiliation":[{"name":"From the Division of Neurocritical Care (S.M.), Departments of Neurology, Anesthesia\/Critical Care and Surgery, University of Massachusetts Medical School, Worcester, MA; Neurocritical Care Service, Departments of Neurology (G.R., J.S.) and Neurosurgery (J.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sims","sequence":"additional","affiliation":[{"name":"From the Division of Neurocritical Care (S.M.), Departments of Neurology, Anesthesia\/Critical Care and Surgery, University of Massachusetts Medical School, Worcester, MA; Neurocritical Care Service, Departments of Neurology (G.R., J.S.) and Neurosurgery (J.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.28.3.660"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.187998"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.191395"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.16.4.562"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.2.383"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0704(05)70274-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-002-0889-5"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570161043476492"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1993.79.4.0537"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1997.87.5.0752"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3103219"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303173081103"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000327698.66596.35"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198204000-00005"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.410140117","article-title":"Neuroleptic malignant syndrome: Successful treatment with dantrolene and bromocriptine","volume":"14","author":"Granato JE","year":"1983","unstructured":"Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S. Neuroleptic malignant syndrome: Successful treatment with dantrolene and bromocriptine. Ann Neurol. 1983;14:89\u201390.","journal-title":"Ann Neurol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1991.tb02031.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(93)90623-S"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-9572(00)00369-5"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.04.058"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-008-9133-4"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-008-9153-0"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-008-9132-5"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000223440.35642.6E"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198310000-00002"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01405268"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200206000-00035"},{"key":"e_1_3_4_28_2","first-page":"388","article-title":"Pharmacology of dantrolene sodium in children","volume":"55","author":"Lietman PS","year":"1974","unstructured":"Lietman PS, Haslam RH, Walcher JR. Pharmacology of dantrolene sodium in children. Arch Phys Med Rehabil. 1974;55:388\u2013392.","journal-title":"Arch Phys Med Rehabil"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03015958"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.110.603159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T13:58:46Z","timestamp":1715608726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.110.603159"}},"subtitle":["A Prospective Pilot Study"],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1161\/STROKEAHA.110.603159"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.110.603159","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"2010-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-12-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}